Progress in Medical Sciences. 2022;
6(2):(79-156)
Progress in the Ascertainment of Vaccines Regarding SARS-CoV-2 During the COVID-19 Pandemic and in the Future
Chrysanthus Chukwuma Sr
Abstract
SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, spatiotemporally evolves or mutates to
its variant with potentialities for adverse opportunistic infections via replications and transmissions
or disseminations. The dissemination and transmission of the Delta variant is accelerating more than
expected partly due to unvaccinated persons not treating the pandemic as seriously as necessary. The
test and tracing service must be effected because a vast proportion ofthe population is unprotected. It
is crucial to restrict movements. Vaccinated persons must socialize indoors in well-ventilated ambients,
and avoid non-essential foreign travels. The evolution of the COVID-19/SARS-CoV-2 pandemic portends
a well-nigh impossible termination of events. It is, therefore, imperative to focus on the cost and not
merely the opportunity cost to control the never-ending SARS-CoV-2/COVID-19 pandemic. There is the
need to make public health system a priority with emphasis on cost sharing and cost saving for vaccines
and other healthcare modalities to reach the poor and the vulnerable populations in developing countries
and elsewhere for safety and protection of lives through enhanced substantial, restorative and sustainable
financing, technical expertise and capacity building.